Drugs for Treating Mental Disorders: Technologies and Global Markets
The global mental health pharmaceutical market can be estimated at $80 billion in 2010. This market is expected to increase at a 1.9% compound annual growth rate (CAGR) over the forecast period to reach a value of $88 billion in 2015.
SCOPE OF REPORT
The subject of the mental health pharmaceutical industry is complex and requires a proper and timely evaluation of current products and most importantly new drug development trends. The geographic scope of this study covers U.S. and global companies. The report identifies the major drug categories in the mental health pharmaceutical industry such as antidepressants, anxiolytics, and other psychiatric drug categories. This study describes current products in each category, identifies current market participants and, notes the new drug development that will affect new opportunities in this area of medicine.
Dr. Marianna Tcherpakov has more than 7 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology, and industrial assay development. She holds her PhD in Molecular Neurobiology and has contributed to a number of scientific publications related to research into central nervous system diseases.